A nanoparticle and its application in the preparation of drugs for treating inflammatory bowel disease
By using nanoparticle technology, combined with immunomodulators and HDAC11 inhibitors, and utilizing Bacillus spore membrane coating, targeted therapy for inflammatory bowel disease has been achieved. This addresses the problem of insufficient intestinal barrier repair by existing drugs and significantly improves intestinal immune homeostasis and mucosal healing.
Patent Information
- Application Number
- CN202611374265.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-07
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2046-09-07
AI Technical Summary
Current drugs for treating inflammatory bowel disease mainly focus on suppressing the inflammatory response, but have limited effect on repairing the intestinal barrier and are difficult to achieve true mucosal healing.
Using nanoparticle technology, SLA nanoparticles are formed by mixing immunomodulators and HDAC11 inhibitors, and CSLA nanoparticles are formed by coating them with Bacillus spore membranes, thereby achieving targeted intestinal immune regulation and barrier repair.
CSLA nanoparticles significantly inhibit macrophage inflammatory responses and neutrophil NET formation, enhance Treg cell function, restore the intestinal mucus barrier, achieve intestinal immune homeostasis reconstruction and mucosal healing, and have good biocompatibility.
Smart Images

Figure CN122894331B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a nanoparticle and its application in the preparation of drugs for treating inflammatory bowel disease. Background Technology
[0002] Inflammatory bowel disease (IBD) is a chronic, relapsing, immune-mediated gastrointestinal disease, primarily including ulcerative colitis (UC) and Crohn's disease (CD). The pathogenesis of IBD is complex. It is generally believed that in genetically susceptible individuals, environmental factors trigger a persistent abnormal immune response between the gut microbiota and the host immune system, which is the core driving factor in the pathogenesis of IBD.
[0003] Immune homeostasis imbalance and intestinal barrier dysfunction are two core pathological features of IBD. Immune homeostasis imbalance is the core driving force behind the persistent inflammation in IBD, manifesting as a dual disorder of innate and adaptive immunity, with a severe disruption of the balance between pro-inflammatory and anti-inflammatory cells. In the inflammatory microenvironment, macrophages are overactivated and undergo PANoptosis—a highly inflammatory programmed cell death pattern integrating pyroptosis, apoptosis, and necroptosis—which integrates multiple cell death signals through the PANoptosome complex, exacerbating tissue damage and the inflammatory cascade. Simultaneously, neutrophils are overactivated and form extracellular neutrophil traps (NETs), playing a crucial role in tissue damage and chronic inflammation. Furthermore, insufficient function or number of regulatory T cells (Tregs) fails to effectively suppress the excessive inflammatory response, leading to persistent inflammation. Therefore, restoring immune homeostasis, particularly by targeting and regulating macrophage inflammatory death and NET formation while enhancing Treg cell function, is a key therapeutic strategy for controlling IBD. Intestinal barrier dysfunction is the initiating factor in the development and progression of IBD. The intestinal barrier, composed of the intestinal epithelial cell layer and its surface mucus layer, is the first line of defense against the invasion of harmful substances and microorganisms. The mucus layer is mainly composed of mucin 2 (MUC2) secreted by goblet cells. In IBD patients, goblet cell function is impaired, and MUC2 expression is dysregulated, leading to a thinner mucus layer. This makes it easier for antigens to contact and activate submucosal immune cells, thereby triggering or exacerbating the inflammatory response. Therefore, repairing the damaged mucus barrier and restoring normal MUC2 expression by targeting specific pathways is one of the key strategies for halting the pathological progression of IBD.
[0004] Currently, clinical treatments for IBD mainly include aminosalicylic acids (such as SASP and 5-ASA), immunosuppressants (such as AZA, 6-MP, MTX, and cyclosporine), and biologics (such as anti-TNF-α agents, anti-integrin agents, and JAK inhibitors). These drugs often have systemic side effects and long-term decreased efficacy. More importantly, existing treatments primarily focus on suppressing the inflammatory response, with limited effects on intestinal barrier repair, making it difficult to achieve true mucosal healing. Therefore, developing novel multi-target therapies that can simultaneously target intestinal immune dysregulation and barrier defects has become a cutting-edge direction in IBD treatment research. Summary of the Invention
[0005] The purpose of this invention is to provide a nanoparticle and its application in the preparation of drugs for treating inflammatory bowel disease, in order to solve the problem that existing treatments mentioned in the background art mainly focus on inhibiting the inflammatory response, while having limited effect on intestinal barrier repair and making it difficult to achieve true mucosal healing.
[0006] To achieve the above objectives, the present invention provides nanoparticles for preparing oral medications for treating inflammatory bowel disease, which are prepared using the following method:
[0007] First, the immunomodulator and HDAC11 inhibitor extracted from natural plants were dissolved in ethanol to prepare solutions with a concentration of 8-12 mg / mL. The two solutions were then mixed thoroughly at a mass ratio of 0.75-1:1 to obtain a first mixture. The first mixture was then added dropwise to deionized water to obtain a second mixture with an ethanol content of 8%, and the mixture was stirred for 20-28 hours. Subsequently, the ethanol was removed by dialysis to obtain an aqueous dispersion of SLA nanoparticles.
[0008] Bacillus spores were taken, homogenized and crushed, and then ultracentrifuged in a 30-60% sucrose density gradient medium to separate and purify the spore outer wall fragments, thus obtaining an aqueous dispersion of coated nanoparticles.
[0009] The SLA nanoparticle aqueous dispersion and the coating nanoparticle aqueous dispersion are mixed at a mass ratio of 0.75~1:1 and incubated at 35~39℃ for 2~4 hours, so that the coating nanoparticles spontaneously coat the surface of the SLA nanoparticles through electrostatic adsorption, forming CSLA nanoparticles with a core-shell structure, i.e., the target nanoparticles.
[0010] In one specific embodiment, the immunomodulator is one of artesunate (ART), berberine, and curcumin; the HDAC11 inhibitor is one of open-ring isolarcisinol (SDG), sodium butyrate, and quaternin A; and the Bacillus spores are one of Bacillus coagulans spores, Bacillus subtilis spores, and Bacillus clausti spores.
[0011] In one specific embodiment, the immunomodulator is artesunate; the HDAC11 inhibitor is open-ring isolarcisinol; and the Bacillus spores are Bacillus coagulans spores.
[0012] In one specific embodiment, the dialysis is performed using a dialysis bag with a molecular weight cutoff of 10 kDa.
[0013] In one specific embodiment, the homogenization and crushing is carried out under a pressure of 80~120MPa, and the ultracentrifugation is carried out at 150000×g for 2~6 hours.
[0014] In one specific embodiment, the SLA nanoparticles have a particle size of 120~140nm, the polydispersity index of the SLA nanoparticle aqueous dispersion is less than 0.1, and the Zeta potential of the SLA nanoparticle aqueous dispersion is -15mV to -20mV.
[0015] The present invention also provides the application of nanoparticles in the preparation of drugs for treating inflammatory bowel disease, wherein the nanoparticles are as described above, and the drugs for treating inflammatory bowel disease are oral formulations.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] I. Synergistic Effect: In vitro cell experiments showed that SLA nanoparticles (co-assembled with ART and SDG) significantly inhibited LPS-induced pro-inflammatory factors in macrophages compared to any single-drug group. The results indicated that SLA nanoparticles significantly inhibited Il-1β and Il-6 mRNA expression more effectively than ART or SDG monotherapy; they also inhibited NF-κB p65 nuclear translocation more effectively than ART or SDG monotherapy; and they significantly inhibited macrophage death more effectively than ART monotherapy. These results demonstrate that SLA nanoparticles, through the synergistic effect of ART and SDG, exhibit a superior combined synergistic effect compared to any single drug in inhibiting macrophage inflammatory responses and cell death.
[0018] II. Colon-Targeted Delivery Efficiency: In vitro simulated digestive fluid release experiments and in vivo imaging results showed that CSLA nanoparticles achieved significant colon-targeted delivery efficiency. In a simulated gastric fluid environment of pH 1.2, the cumulative drug release rate of CSLA nanoparticles after 24 hours was extremely low, close to zero, indicating that the spore membrane shell effectively protects the drug from gastric acid erosion. In a simulated intestinal fluid environment of pH 7.4, the drug was rapidly released, with a cumulative release rate of 81.94% after 24 hours, achieving intestinal-targeted release. In vivo imaging showed that 12 hours after oral administration, the fluorescence signal of uncoated SLA nanoparticles was significantly weakened, while the CSLA group still maintained a strong signal; 24 hours after administration, the signal of the SLA group almost disappeared, while a significant intestinal retention signal could still be detected in the CSLA group. These results indicate that CSLA nanoparticles, through biomimetic spore membrane coating, achieve stable gastric and intestinal release with colon-targeted delivery characteristics, and significantly prolong the retention time in inflamed intestinal sites, solving the technical challenge of the difficulty of effective enrichment of conventional oral formulations at colonic lesion sites.
[0019] III. Immunomodulatory Effects: In the DSS-induced IBD mouse model, CSLA nanoparticles showed significantly better remodeling effects on the intestinal immune microenvironment than the control groups. Results showed that the CSLA group exhibited the most significant reductions in neutrophil infiltration, the most significant decrease in the proportion of M1 macrophages, and a significant reduction in CD8-positive T cell infiltration (ART and SDG monotherapy showed no significant changes). The proportion of Foxp3-positive Treg cells also increased most significantly, and the disease activity index decreased most significantly. These results indicate that CSLA nanoparticles are superior to SLA nanoparticles and individual drug groups in inhibiting pro-inflammatory immune cell infiltration and expanding regulatory T cells, effectively restoring intestinal immune homeostasis.
[0020] IV. Mucosal Barrier Repair Effect: In the DSS-induced IBD mouse model, CSLA nanoparticles showed significantly better repair effects on the intestinal mucus barrier than the control groups. Experimental results showed that the CSLA group exhibited the most significant recovery in MUC2 protein expression, the most significant improvement in alicin blue-positive area and mucosal coverage, and the most significant increase in CDX2 expression. Notably, ART intervention mainly promoted mucus secretion, SDG intervention mainly increased mucosal coverage, while SLA and CSLA nanoparticles significantly improved both simultaneously, with CSLA showing the best effect. These results indicate that CSLA nanoparticles, through SDG-mediated activation of the HDAC11-CDX2-MUC2 pathway, synergistically repair the intestinal mucus barrier, demonstrating significantly better effects than the single-drug groups in terms of MUC2 expression recovery and mucus layer reconstruction.
[0021] V. Dual Inhibition of PANoptosis and NETs: Mechanistic studies have revealed that the core component of CSLA nanoparticles, ART, possesses a dual anti-inflammatory mechanism. Experimental results show that ART pretreatment dose-dependently attenuates the LPS-induced interaction between ZBP1 and RIPK3, and reduces the expression levels of PANoptosis-related effector proteins Caspase-6, ZBP1, and RIPK3, indicating that ART inhibits PANoptosis by blocking the assembly of the PANoptosome complex. Simultaneously, ART significantly reduces ROS levels in PMA-stimulated neutrophils and dose-dependently decreases CitH3 expression, extracellular DNA distribution, and dsDNA concentration in the supernatant, indicating that ART inhibits NET formation by suppressing oxidative stress. This invention is the first to reveal that ART achieves its anti-inflammatory effect by dually targeting PANoptosis and NETs.
[0022] VI. In vivo safety: Long-term toxicity studies demonstrated that CSLA nanoparticles possess good biocompatibility. After continuous oral administration of CSLA nanoparticles for 2, 4, and 6 weeks, there were no significant differences in serum liver function indicators ALT and AST, and kidney function indicator Cre, compared with the normal control group in mice. H&E staining of major organs (heart, liver, lungs, kidneys, stomach, and tongue) showed no significant pathological changes. These results indicate that this nanosystem exhibits good biocompatibility with long-term use at therapeutic doses and does not show cumulative toxicity.
[0023] VII. Multi-target regulation validated by single-cell transcriptomics: Single-cell sequencing analysis comprehensively validated the multi-target regulatory mechanism of CSLA nanoparticles. In macrophages, CSLA intervention significantly downregulated the expression of pattern recognition receptors Clec4e and Cd14, and pro-inflammatory mediators S100a8 and Nos2, while upregulating the expression of M2 macrophage markers Arg1 and Il10. In neutrophils, CSLA significantly downregulated the expression of chemotaxis-related genes Itgam and NETs formation-related genes Padi4 and Mpo. In goblet cells, CSLA significantly restored the expression of mucin synthesis and processing-related genes Muc2 and Tff3, and downregulated the expression of genes related to mucosal metabolism activation. In T cell subsets, CSLA treatment significantly reduced the frequency of CD8-positive T cells, expanded the Treg cell population, and Treg cells showed enrichment of differentially expressed genes in Th17 cell differentiation and the JAK-STAT signaling pathway. In NK cells and CD8-positive T cells, CSLA significantly downregulated the expression of pro-inflammatory and cytotoxic genes Gzmb, Ifng, and Mmp9. The above results demonstrate that single-cell transcriptomics globally confirms that CSLA nanoparticles reconstruct intestinal immune-epithelial homeostasis by simultaneously regulating innate immune cells, adaptive immune cells, and intestinal epithelial cells, providing direct molecular-level evidence for multi-target therapy of IBD.
[0024] In summary, this invention represents a substantial improvement over existing technologies in the following ways: SLA nanoparticles exhibit significantly better inhibitory effects on pro-inflammatory factors than ART or SDG monotherapy; CSLA achieves stable gastric and intestinal release, and remains significantly retained 24 hours after oral administration; it is the first to reveal that ART inhibits PANoptosis by blocking the ZBP1-RIPK3 interaction and inhibits NETs by reducing ROS; SDG restores MUC2 expression through the HDAC11-CDX2-MUC2 axis, and its effect disappears after CDX2 knockdown; CSLA significantly reduces the infiltration of neutrophils, M1 macrophages, and CD8-positive T cells, and increases the proportion of Treg cells; single-cell sequencing confirms that CSLA synchronously regulates eight cell populations and reconstructs immune-epithelial homeostasis; after 6 weeks of continuous administration, no pathological changes were observed in major organs, and liver and kidney function remained normal.
[0025] In addition to the objectives, features, and advantages described above, the present invention has other objectives, features, and advantages. The present invention will now be described in further detail. Attached Figure Description
[0026] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:
[0027] Figure 1 This is a dynamic light scattering particle size distribution diagram of SLA nanoparticles according to an embodiment of the present invention; the horizontal axis of the diagram represents the particle size (nm), and the vertical axis represents the intensity percentage (%); the results show that the average particle size of the SLA nanoparticles is 132.6nm, the polydispersity index (PDI) is less than 0.1, and the distribution is uniform; this diagram proves that the nanoparticles have a suitable particle size range and can achieve passive targeted enrichment at the site of inflammation.
[0028] Figure 2 This is a Zeta potential distribution diagram of SLA nanoparticles according to an embodiment of the present invention; the results show that the Zeta potential of the SLA nanoparticles is -17.1mV, and the surface is negatively charged; this negative charge is beneficial for the nanoparticles to maintain long-term colloidal stability in solution through electrostatic repulsion and prevent particle aggregation.
[0029] Figure 3 This is a transmission electron microscope image of SLA nanoparticles according to an embodiment of the present invention; the scale bar in the image is 100 nm; the results show that the SLA nanoparticles are regular spherical, well dispersed, and have uniform morphology; this image confirms the successful construction of carrier-free self-assembled nanoparticles from a microscopic morphology perspective.
[0030] Figure 4This is a UV-Vis absorption spectrum of SLA, SDG, ART, and their physical mixture according to an embodiment of the present invention. The horizontal axis represents wavelength (nm), and the vertical axis represents absorbance. The results show that the SLA nanoparticles exhibit a characteristic absorption peak at 282 nm, which is significantly shifted compared to the ART monomer, SDG monomer, and their physical mixture. This figure provides spectroscopic evidence confirming that ART and SDG successfully self-assemble through intermolecular interactions.
[0031] Figure 5 This figure illustrates the particle size stability changes of SLA nanoparticles in different media according to an embodiment of the present invention. Figure A shows the particle size change curves of the SLA nanoparticles over 24 hours in deionized water, NaCl solution, urea solution, and SDS solution; Figure B shows the UV-Vis absorption spectra of the corresponding media. The results show that the SLA nanoparticles remain stable in NaCl and urea solutions, while the particle size significantly increases to the micrometer scale in SDS solution, and the UV absorption peak undergoes a significant change. This figure demonstrates that hydrophobic interactions are the main driving force maintaining the structural stability of the SLA nanoparticles.
[0032] Figure 6 This is a transmission electron microscope image of Bacillus coagulans spore membrane for biomimetic coating according to an embodiment of the present invention; wherein, the bar of icon A is 1 μm and the bar of icon B is 200 nm; the results show that the extracted spore membrane has an intact structure and can be used as a biomimetic coating material; this image provides a material basis for the construction of CSLA nanoparticles.
[0033] Figure 7 This is a transmission electron microscope image of CSLA nanoparticles according to an embodiment of the present invention; the scale bar in the image is 100 nm; the results show that the CSLA nanoparticles exhibit a typical core-shell structure, that is, the SLA core is wrapped by a layer of uneven spore membrane shell; this image confirms the successful construction of the biomimetic coating from a microscopic morphological perspective.
[0034] Figure 8 This is a cumulative drug release curve of CSLA nanoparticles in different simulated digestive fluids according to an embodiment of the present invention; the horizontal axis of the figure is time (h), and the vertical axis is the cumulative release rate (%); the results show that in simulated gastric fluid (pH 1.2), the cumulative drug release rate of CSLA nanoparticles after 24 hours is extremely low, close to zero; in simulated intestinal fluid (pH 7.4), the drug is released rapidly, with a cumulative release rate of 81.94% after 24 hours; this figure proves that CSLA nanoparticles have excellent gastric acid resistance and colon-targeted release characteristics.
[0035] Figure 9This is a confocal microscopy image of the uptake of CSLA nanoparticles in LS174T intestinal epithelial cells according to an embodiment of the present invention; AC in the figure are confocal images of CSLA nanoparticles and cells after 2 hours, 12 hours and 24 hours respectively, with a scale bar of 50 μm; the results show that the intracellular fluorescence signal is weak after 2 hours of incubation, the fluorescence intensity gradually increases after 12 hours, and significantly enriched fluorescent particles are visible in the cells after 24 hours.
[0036] Figure 10 yes Figure 9 Comparison of average fluorescence intensity of CSLA nanoparticles with cells after 2 hours, 12 hours and 24 hours of incubation; flow cytometry quantification showed that the cell uptake rate reached 92.5% after 24 hours of incubation, with the highest average fluorescence intensity; Figure 9 and Figure 10 This demonstrates that CSLA nanoparticles can efficiently enter intestinal epithelial cells.
[0037] Figures 11-12 This is an in vivo imaging image of the distribution and retention of CSLA nanoparticles in a DSS-induced IBD mouse model according to an embodiment of the present invention; wherein... Figure 11 These are in vivo fluorescence images of mice at 0, 12, and 24 hours after oral administration. Figure 12 This is a fluorescence imaging image of the ex vivo gastrointestinal tract. The results show that at 2 hours, both the SLA and CSLA groups showed obvious fluorescence in the gastrointestinal tract. At 12 hours, the fluorescence signal of the SLA group decreased significantly, while the CSLA group still maintained a strong signal. At 24 hours, the signal of the SLA group almost disappeared, while the CSLA group still showed obvious intestinal retention signal. This figure proves that the retention time of CSLA nanoparticles in vivo is significantly prolonged, achieving colon-targeted delivery.
[0038] Figure 13 This is a diagram illustrating the mechanism by which ART inhibits macrophage PANoptosis according to an embodiment of the present invention; Figure A is an electrophoresis diagram of the interaction between ZBP1 and RIPK3 detected by immunoprecipitation, and Figure B is a diagram of the expression of PANoptosis effector proteins Caspase-6, ZBP1, and RIPK3 detected by Western blot; the results show that ART pretreatment dose-dependently attenuates LPS-induced ZBP1-RIPK3 interaction and reduces the protein expression levels of Caspase-6, ZBP1, and RIPK3; this figure demonstrates that ART inhibits macrophage PANoptosis by blocking the assembly of the PANoptosome complex.
[0039] Figures 14-16 This is a diagram illustrating the mechanism of action of ART in inhibiting neutrophil NET formation according to an embodiment of the present invention; wherein, Figure 15The images show flow cytometry data of ROS levels in neutrophils after treatment with different concentrations of ART. Image a is a staining image, and image b is a quantitative image. Figure 14 The images show CitH3 immunofluorescence staining and quantification, where image a is the staining image and image b is the quantification image. Figure 16 The results show that ART significantly reduced PMA-induced intracellular ROS levels in neutrophils and dose-dependently reduced CitH3 expression and extracellular DNA release. This figure demonstrates that ART inhibits NETs formation by suppressing the oxidative stress pathway.
[0040] Figure 17 This is a chromatin immunoprecipitation quantitative PCR result of SDG regulating histone acetylation in the Cdx2 promoter region according to an embodiment of the present invention; specifically, it is an electrophoresis diagram of the enrichment level of H3K14ac in the Cdx2 promoter region of LS174T cells after SDG treatment; the results show that SDG treatment significantly enhances the H3K14ac level in the Cdx2 promoter region; this figure proves that SDG activates CDX2 transcription through epigenetic regulation.
[0041] Figures 18-19 This is a histopathological evaluation image of colon tissue in mice treated with CSLA nanoparticles according to an embodiment of the present invention, after DSS-induced IBD. Figure 18 H&E stained colon tissue, scale bar 50 μm; Figure 19 The results show that the colonic mucosa structure in the model group was severely damaged, with a large number of inflammatory cells infiltrating; the colonic mucosa structure in the CSLA group was the most intact, the inflammatory cell infiltration was the least, and the pathological score was the lowest. This figure proves that CSLA nanoparticles can significantly reduce intestinal tissue pathological damage.
[0042] Figures 20-21 This is an immunohistochemical image of colonic MUC2 expression in mice after treatment with CSLA nanoparticles in DSS-induced IBD, according to an embodiment of the present invention; wherein, Figure 20 Immunohistochemical staining image of MUC2, scale bar 50 μm; Figure 21 The bar chart shows the relative quantitative expression of MUC2. The results show that MUC2 expression was significantly reduced in the model group and the most significant recovery of MUC2 expression was observed in the CSLA group. This figure demonstrates that CSLA nanoparticles can effectively repair the intestinal mucus barrier.
[0043] Figures 22-25 This is an immunofluorescence assay of the intestinal immune microenvironment regulation after CSLA nanoparticle treatment in DSS-induced IBD mice, according to an embodiment of the present invention; wherein... Figure 22 Image of Ly6G immunofluorescence staining, scale bar 50 μm; Figure 23 Immunofluorescence staining images of CD68 and iNOS, scale bar at 50 μm; Figure 24 Immunohistochemical staining images of CD8, CD4, and Foxp3, with a scale bar of 100 μm; Figure 25 Figure 1 shows the quantitative analysis of CD4-positive and Foxp3-positive cells based on IHC staining. Figure 2a shows the quantitative analysis of CD4-positive cells, and Figure 3b shows the quantitative analysis of Foxp3-positive cells. The results show that the CSLA group exhibited the most significant reduction in neutrophil infiltration, the most significant decrease in the proportion of M1 macrophages, and the highest proportion of Foxp3+ Treg cells. This figure demonstrates that CSLA nanoparticles can effectively inhibit the infiltration of pro-inflammatory immune cells and expand regulatory T cells, thereby restoring intestinal immune homeostasis.
[0044] Figures 26-28 This is a diagram showing the results of single-cell transcriptomics analysis of CSLA nanoparticles after treatment of DSS-induced IBD mice according to an embodiment of the present invention; wherein, Figure 26 This is a violin diagram illustrating representative gene expression in macrophages. Figure 27 This is a violin diagram showing representative gene expression in neutrophils. Figure 28 This is a violin diagram showing the expression of representative functional genes in goblet cells. The results showed that after CSLA intervention, macrophages downregulated Clec4e, Cd14, S100a8, and Nos2, and upregulated Arg1 and Il10; neutrophils downregulated Itgam, Padi4, and Mpo; and goblet cells upregulated Muc2 and Tff3. This diagram demonstrates, at the single-cell level, the multi-target mechanism by which CSLA nanoparticles simultaneously regulate macrophage reprogramming, neutrophil inhibition, and goblet cell repair.
[0045] Figures 29-30 This is a safety evaluation diagram of long-term drug delivery of CSLA nanoparticles according to an embodiment of the present invention; wherein, Figure 29 Images of H&E staining of major organs (heart, liver, lung, kidney, stomach, and tongue) in mice after 2, 4, and 6 weeks of continuous drug administration, with a scale bar of 100 μm; Figure 30 The figures show bar charts of plasma ALT, AST, and Cre levels in mice at different administration durations, with figure a representing ALT levels, figure b representing AST levels, and figure c representing Cre levels. The results showed that after 6 weeks of continuous administration, no significant pathological changes were observed in any organ, and there were no significant differences in liver and kidney function indicators compared with the normal control group. This figure demonstrates that CSLA nanoparticles have good long-term biosafety. Detailed Implementation
[0046] The embodiments of the present invention will be described in detail below. The specific embodiments described herein are merely illustrative of the present invention and are not intended to limit the present invention.
[0047] The present invention discloses nanoparticles for preparing oral medications for treating inflammatory bowel disease, which are prepared by the following method:
[0048] The first step involved constructing a carrier-free, self-assembling core, namely SLA nanoparticles. Artesunate (ART) and open-ring isolarcitabine (SDG) were dissolved separately in ethanol to prepare solutions of 10 mg / mL. The two solutions were then mixed thoroughly at a 1:1 mass ratio. Under magnetic stirring, the mixture was slowly added dropwise to deionized water until the final ethanol content reached 8%, and stirring continued for 24 hours. Subsequently, the ethanol was removed using a dialysis bag with a molecular weight cutoff of 10 kDa, yielding an aqueous dispersion of SLA nanoparticles. Artesunate can also be replaced by other anti-inflammatory natural products such as berberine and curcumin. Open-ring isolarcitabine can be replaced by other HDAC11 inhibitors such as sodium butyrate and trogostatin A.
[0049] Dynamic light scattering (DLS) analysis revealed that the SLA nanoparticles had an average particle size of 132.6 nm, a polydispersity index (PDI) of less than 0.1, and a zeta potential of -17.1 mV. Transmission electron microscopy (TEM) observation showed that the nanoparticles were regularly spherical and uniform in size. UV-Vis absorption spectroscopy showed a characteristic absorption peak at 282 nm, which shifted compared to the monomer and physical mixtures, confirming the successful self-assembly of drug molecules through hydrophobic interactions. Stability studies showed that the SLA nanoparticles remained stable in NaCl and urea solutions, but the particle size significantly increased to the micrometer scale in sodium dodecyl sulfate (SDS), indicating that hydrophobic interactions were the main driving force maintaining the structural stability of the nanoparticles.
[0050] The second step involves constructing CSLA nanoparticles with a core-shell structure. Bacillus coagulans spores were homogenized at 100 MPa and then ultracentrifuged at 150,000 × g for 4 hours in a 30–60% sucrose density gradient medium to separate and purify the spore outer wall fragments, yielding an aqueous dispersion of coated nanoparticles (CNs). The SLA nanoparticle aqueous dispersion and the coated nanoparticle aqueous dispersion were mixed at a 1:1 mass ratio and incubated at 37°C for 2 hours. This allowed the coated nanoparticles to spontaneously coat the surface of the SLA nanoparticles through electrostatic adsorption, forming CSLA nanoparticles with a core-shell structure.
[0051] DLS measurements showed that the average particle size of the CSLA nanoparticles increased to 148 nm, while still maintaining a relatively narrow particle size distribution. TEM images directly revealed a typical core-shell structure, where the SLA core is encased in a non-uniform membrane-like shell.
[0052] The third step was to achieve colon-targeted delivery. CSLA nanoparticles were placed in simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 7.4), and the cumulative drug release rate was measured over 24 hours at 37°C.
[0053] The results showed that in simulated gastric fluid, the cumulative drug release rate of CSLA nanoparticles over 24 hours was extremely low (close to zero), indicating that the spore membrane shell effectively protected the drug from gastric acid erosion; in simulated intestinal fluid, the drug was released rapidly, with a cumulative release rate of 81.94% over 24 hours, indicating that CSLA nanoparticles can selectively dissociate and release the drug in the intestinal environment.
[0054] The fourth step is to achieve synergistic treatment of immune regulation and barrier repair.
[0055] Immunomodulatory effects of ART:
[0056] 1. Inhibition of macrophage inflammatory response: In LPS-induced macrophage-mediated blastocystic disease (BMDMs), ART significantly reduced the mRNA expression levels of pro-inflammatory factors Il-1β, Il-6, and Tnf-α, while enhancing the expression of IL-4-induced anti-inflammatory factors Il-10 and Reg-3. Immunofluorescence staining showed that ART effectively inhibited LPS-induced NF-κB p65 nuclear translocation.
[0057] 2. Inhibition of macrophage PANoptosis: PI staining showed that ART significantly reduced LPS-induced macrophage death. Co-IP assays indicated that ART pretreatment dose-dependently attenuated LPS-induced interaction between ZBP1 and RIPK3. Western blot results showed that ART reduced the expression levels of PANoptosis-related effector proteins (Caspase-6, ZBP1, RIPK3).
[0058] 3. Inhibition of NET formation in neutrophils: In PMA-stimulated neutrophils, ART dose-dependently reduced CitH3 expression, extracellular DNA distribution, and dsDNA concentration in the supernatant. Mechanistic studies showed that ART did not alter the mRNA expression of NET structure-related genes (Mpo, Elastase, Pad4), but significantly reduced intracellular ROS levels.
[0059] 4. No significant effect on Th1 cells: ART treatment does not change the expression level of Ifnγ in Th1 cells, indicating that its immunomodulatory effect is selective.
[0060] SDG's barrier repair function:
[0061] 1. Screening and Validation of HDAC11 Inhibitors: Through virtual molecular screening of 50,000 natural compounds, combined with in vitro validation, it was found that SDG can effectively upregulate MUC2 expression in LS174T cells. Molecular docking showed that SDG specifically binds to the active site of HDAC11.
[0062] 2. Regulation mechanism of HDAC11-CDX2-MUC2 axis: SDG treatment significantly increased the mRNA and protein expression levels of CDX2 in LS174T cells; after knockdown of Cdx2, the promoting effect of SDG on Muc2 expression was significantly weakened, confirming that CDX2 is a key downstream mediator of SDG; ChIP-qPCR experiments showed that SDG significantly enhanced the level of histone H3 lysine 14 acetylation (H3K14ac) in the Cdx2 promoter region.
[0063] 3. Recovery of MUC2 expression in IBD animal models: Immunohistochemical staining showed that the MUC2 protein level was significantly reduced and HDAC11 expression was significantly increased in the colon tissue of DSS-induced IBD mice, while the levels of XBP1 and p-STAT3 remained unchanged. SDG treatment could restore MUC2 expression.
[0064] The fifth step is cellular uptake and retention in the body.
[0065] Cellular uptake: FITC-labeled CSLA nanoparticles were co-incubated with LS174T cells. Confocal microscopy showed that cell uptake was low after 2 hours of incubation, fluorescence intensity gradually increased after 12 hours, and significant intracellular enrichment occurred after 24 hours. Flow cytometry quantitative analysis showed that the cell uptake rate reached 92.5% after 24 hours of incubation, with the highest average fluorescence intensity.
[0066] In vivo retention: Two hours after oral administration to mice, significant fluorescent signals were observed in the gastrointestinal tract of both the SLA and CSLA groups. At 12 hours, the fluorescence signal in the SLA group significantly decreased, while the CSLA group maintained a strong signal. At 24 hours, the signal in the SLA group almost disappeared, while significant intestinal retention was still observed in the CSLA group. The results of ex vivo imaging were consistent with those of in vivo imaging.
[0067] Step 6: In vivo pharmacodynamic evaluation.
[0068] In a DSS-induced IBD mouse model (administered via gavage on days 1, 3, and 5 after 7 days of modeling), CSLA nanoparticles showed the best therapeutic effect: 1. Clinical indicators: The CSLA group showed the most significant weight recovery, the most significant decrease in the Disease Activity Index (DAI) score, and the best recovery in colon length. 2. Histopathology: H&E staining showed that the CSLA group had the most intact colonic mucosal structure, the mildest inflammatory cell infiltration, and the lowest pathological score. 3. Apoptosis and proliferation: TUNEL staining showed that the CSLA group had the lowest level of apoptosis; immunohistochemistry showed that the CSLA group had the lowest expression of cleaved caspase-3 and the highest rate of Ki-67 positive cells. 4. Inflammatory factors: The CSLA group showed the most significant decrease in IL-1β expression. 5. Immune microenvironment remodeling: Neutrophil (Ly6G+) infiltration was most significantly reduced; the proportion of M1 macrophages (CD68+ / iNOS+) was most significantly reduced; CD8+ T cell infiltration was significantly reduced (ART and SDG monotherapy had no significant effect); the proportion of Foxp3+ Treg cells was significantly increased. 6. Mucosal barrier repair: Alixin blue staining showed that the CSLA group had the best recovery in mucus layer thickness and coverage; MUC2 immunohistochemical staining showed that the CSLA group had the most significant recovery in MUC2 expression.
[0069] Step 7: Single-cell transcriptomics analysis.
[0070] Single-cell sequencing analysis of colon tissue from the IBD control group and the CSLA treatment group revealed the following results: 1. Macrophages: CSLA intervention significantly downregulated the expression of pattern recognition receptors (Clec4e, Cd14) and pro-inflammatory mediators (S100a8, Nos2), while upregulating the expression of M2 macrophage markers (Arg1, Il10). KEGG enrichment analysis showed significant inhibition of NF-κB and TNF signaling pathways. 2. Neutrophils: CSLA significantly downregulated the expression of chemokine-related genes (Itgam) and NETs formation-related genes (Padi4, Mpo). 3. Goblet cells: CSLA significantly restored the expression of genes related to mucin synthesis and processing (Muc2, Tff3) and downregulated the expression of genes related to mucosal metabolism activation. 4. T cell subsets: CSLA treatment significantly reduced the frequency of CD8+ T cells and expanded the Treg cell population. Treg cell DEGs were enriched in Th17 cell differentiation and the JAK-STAT signaling pathway. 5. NK cells and CD8+ T cells: CSLA significantly downregulated the expression of pro-inflammatory and cytotoxic genes (Gzmb, Ifng, Mmp9).
[0071] Step 8: Safety assessment.
[0072] 1. Short-term safety (DSS model): CSLA significantly reduced DSS-induced liver and tongue mucosal damage; no significant morphological differences were observed in the heart, kidneys, and stomach; serum ALT, AST, and Cre levels were significantly restored.
[0073] 2. Long-term safety (continuous gavage administration to healthy mice for 2, 4, and 6 weeks): H&E staining showed no obvious pathological changes in the heart, liver, lungs, tongue, kidneys, and stomach; serum ALT, AST, and Cre levels were not significantly different from those in the control group.
[0074] The present invention relates to the application of a nanoparticle in the preparation of a drug for treating inflammatory bowel disease, wherein the nanoparticle is the aforementioned nanoparticle, and the drug for treating inflammatory bowel disease is an oral formulation.
[0075] Example 1
[0076] Preparation and characterization of self-assembled SLA nanoparticles.
[0077] 1. Preparation of SLA nanoparticles. Artesunate (ART) and open-ring isolar resin phenol (SDG) were dissolved in ethanol to prepare solutions of 10 mg / mL. The two solutions were mixed thoroughly at a mass ratio of 1:1. Under magnetic stirring, the mixture was slowly added dropwise to deionized water until the final ethanol content was 8%, and stirring was continued for 24 hours. The resulting suspension was then transferred to a dialysis bag with a molecular weight cutoff of 10 kDa, and dialyzed against deionized water to remove ethanol, yielding an aqueous dispersion of SLA nanoparticles.
[0078] 2. Particle Size, Potential, and Morphology Characterization. Dynamic light scattering (DLS) was used to determine the particle size, polydispersity index (PDI), and zeta potential of the SLA nanoparticles. The results showed that the average particle size of the SLA nanoparticles was 132.6 nm, the PDI was less than 0.1, and the zeta potential was -17.1 mV. Transmission electron microscopy (TEM) was used to observe the morphology of the nanoparticles, revealing that the particles were regular spheres of uniform size.
[0079] 3. UV-Vis absorption spectroscopy analysis. A UV-Vis spectrophotometer was used to scan SLA nanoparticles, ART monomers, SDG monomers, and their physical mixtures. The results showed that SLA nanoparticles exhibited a characteristic absorption peak at 282 nm, which shifted compared to the monomers and physical mixtures, confirming that the drug molecules successfully self-assembled through interactions.
[0080] 4. Assembly Driving Force Study. SLA nanoparticles were co-incubated with sodium chloride (NaCl), urea, and sodium dodecyl sulfate (SDS) for 24 hours, and the particle size change was measured. The results showed that the particle size of SLA nanoparticles remained stable in NaCl and urea solutions; in SDS solution, the particle size increased significantly to the micrometer scale, indicating that hydrophobic interactions are the main driving force for maintaining the structural stability of SLA nanoparticles.
[0081] Example 2
[0082] Preparation and characterization of CSLA nanoparticles.
[0083] 1. Extraction of Bacillus coagulans spore membrane. Bacillus coagulans spores were homogenized and crushed under 100 MPa pressure, and then subjected to ultracentrifugation at 150,000 × g for 4 hours in a 30-60% sucrose density gradient medium to separate and purify the spore outer wall fragments, obtaining an aqueous dispersion of coated nanoparticles (CNs).
[0084] 2. Preparation of CSLA nanoparticles. The SLA nanoparticles prepared in Example 1 were mixed with the coated nanoparticle aqueous dispersion at a mass ratio of 1:1 and incubated at 37°C for 2 hours, so that the coated nanoparticles spontaneously coated the surface of the SLA nanoparticles through electrostatic adsorption, thus forming CSLA nanoparticles.
[0085] 3. Characterization: The particle size and PDI of CSLA nanoparticles were determined by DLS. The results showed that the average particle size increased to approximately 148 nm, while still maintaining a relatively narrow particle size distribution. TEM observation revealed a typical core-shell structure, i.e., the SLA core was wrapped by a non-uniform membrane-like outer shell.
[0086] 4. pH-responsive release experiment. CSLA nanoparticles were placed in simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 7.4), respectively, and shaken at 37°C. Samples were taken at different time points, and drug concentration was determined by high-performance liquid chromatography (HPLC), and the cumulative release rate was calculated. The results showed that the cumulative drug release rate in SGF was extremely low (close to zero) after 24 hours; while in SIF, the drug was released rapidly, with a cumulative release rate of 81.94% after 24 hours.
[0087] Example 3
[0088] Cellular uptake experiment.
[0089] 1. Fluorescent labeling: CSLA nanoparticles were fluorescently labeled using FITC.
[0090] 2. Cell incubation and confocal microscopy observation. Human colorectal cancer cells LS174T were seeded in confocal culture dishes and cultured for 24 hours. FITC-labeled CSLA nanoparticles (50 μg / mL) were added, and the cells were incubated for 2, 12, and 24 hours, respectively. After incubation, the cells were washed with PBS, fixed with 4% paraformaldehyde, and the nuclei were stained with DAPI and the cytoskeleton was stained with phalloidin. The cells were then observed under a confocal microscope. The results showed that the intracellular fluorescence signal was weak at 2 hours of incubation; the fluorescence intensity gradually increased at 12 hours; and significantly enriched fluorescent particles were visible in the cells at 24 hours.
[0091] 3. Quantitative analysis by flow cytometry. LS174T cells were seeded in 6-well plates and incubated with FITC-labeled CSLA nanoparticles for 2, 12, and 24 hours as described above. Cells were then digested and collected, and the mean fluorescence intensity (MFI) and positive cell rate were detected by flow cytometry. The results showed that the cell uptake rate reached 92.5% after 24 hours of incubation, with the highest MFI value.
[0092] Example 4
[0093] In vitro anti-inflammatory and barrier repair experiments.
[0094] 1. Macrophage Inflammatory Factor Expression. Mouse bone marrow-derived macrophages (BMDMs) were isolated and cultured, and stimulated with LPS (1 μg / mL) or IL4 (20 ng / mL), while simultaneously treated with ART (10 μM), SDG (40 μM), or SLA nanoparticles (containing equal amounts of ART and SDG). The mRNA expression levels of pro-inflammatory factors (Il1β, Il6, Tnfα) and anti-inflammatory factors (Il10, Reg3) were detected by qRTPCR. Results showed that under LPS stimulation, both ART and SDG significantly inhibited the expression of pro-inflammatory factors, while the inhibitory effect of SLA nanoparticles was significantly better than either single drug. Under IL4 stimulation, the expression of anti-inflammatory factors increased in all treatment groups, but there were no significant differences between groups.
[0095] 2. Detection of NFκB p65 nuclear translocation. BMDMs were seeded in confocal culture dishes and treated with LPS stimulation simultaneously with ART, SDG, or SLA nanoparticles. Immunofluorescence staining was used to observe NFκB p65 nuclear translocation. The results showed that LPS stimulation induced significant p65 nuclear translocation, while ART, SDG, and SLA nanoparticles all inhibited nuclear translocation, with SLA nanoparticles showing the best effect.
[0096] 3. Macrophage PANoptosis Detection. BMDMs were stimulated with LPS and pretreated with ART (5, 10 μM). Cell death was detected by PI staining. The results showed that ART dose-dependently reduced the rate of LPS-induced PI-positive cells. Co-immunoprecipitation (CoIP) experiments showed that ART attenuated the interaction between ZBP1 and RIPK3; Western blot showed that ART reduced the protein levels of Caspase6, ZBP1, and RIPK3.
[0097] 4. Neutrophil NET formation detection. Neutrophils were isolated from mouse bone marrow and stimulated with PMA (100 nM) for 4 hours to induce NET formation, while simultaneously treated with different concentrations of ART. Immunofluorescence staining was used to detect CitH3 expression and SytoxGreen-labeled extracellular DNA, and the concentration of dsDNA in the supernatant was measured. The results showed that ART dose-dependently reduced CitH3 fluorescence intensity, extracellular DNA area, and dsDNA content. Simultaneously, ART significantly reduced PMA-induced intracellular ROS levels, but had no significant effect on the mRNA expression of Mpo, Pad4, and Elastase.
[0098] 5. Muc2 and CDX2 expression in goblet cells. LS174T cells were treated with ART, SDG, or SLA nanoparticles, respectively. qRT-PCR was used to detect the mRNA levels of Muc2 and Cdx2, and Western blot was used to detect the protein levels of Muc2, CDX2, and HDAC11. The results showed that SDG and SLA nanoparticles significantly upregulated the mRNA and protein levels of Muc2 and Cdx2 and decreased the HDAC11 protein level, while ART had no significant effect.
[0099] 6. Gene silencing assay. Cdx2 expression was knocked down in LS174T cells using siRNA transfection, followed by treatment with SDG (40 μM), and Muc2 mRNA expression was detected. Results showed that knocking down Cdx2 significantly weakened the effect of SDG in promoting Muc2 expression.
[0100] 7. ChIP qPCR experiment. LS174T cells treated with SDG were collected. DNA fragments were enriched using a chromatin immunoprecipitation (ChIP) kit with anti-H3K14ac antibody, and qPCR was used to detect the enrichment of the Cdx2 promoter region. Results showed that SDG treatment significantly enhanced the H3K14ac level in the Cdx2 promoter region.
[0101] Example 5
[0102] Efficacy experiment of DSS-induced IBD mouse model.
[0103] 1. Animal Grouping and Drug Administration. Eight-week-old male C57BL / 6J mice were randomly divided into six groups: normal control group, DSS model group, ART group, SDG group, SLA nanoparticle group, and CSLA nanoparticle group, with six mice in each group. Except for the normal control group, the other groups were allowed free access to 2.5% DSS solution for 7 consecutive days to induce acute colitis. On days 1, 3, and 5 after modeling, the corresponding drugs were administered by gavage (ART and SDG doses were calculated based on 10 mg / kg, and SLA and CSLA were administered at equivalent doses). The normal control group and the model group were given an equal volume of physiological saline.
[0104] 2. Disease Activity Index Assessment. Mouse body weight, fecal characteristics, and fecal blood loss were recorded daily, and the Disease Activity Index (DAI) was calculated using a standard scoring system. Results showed that compared to the model group, all treatment groups exhibited lower DAI scores, with the CSLA group showing the most significant reduction and the best weight recovery.
[0105] 3. Colon length and histopathological examination. Mice were sacrificed on day 9, and their colons were harvested to measure length and stained with H&E. Results showed that the colon length in the model group was significantly shortened, with severe damage to the mucosal structure and extensive infiltration of inflammatory cells. All treatment groups showed improvement, with the CSLA group showing the most significant recovery in colon length and the lowest histopathological score.
[0106] 4. Immunohistochemistry and Immunofluorescence Staining. Colon tissue sections were obtained and subjected to immunohistochemistry or immunofluorescence staining. The results showed that: MUC2 staining: MUC2 expression was most significantly restored in the CSLA group; CDX2 staining: CDX2 expression in the CSLA group was significantly higher than that in the model group; Ly6G staining: Neutrophil infiltration was least in the CSLA group; CD68 / iNOS double staining: The proportion of M1 macrophages was lowest in the CSLA group; CD8 staining: CD8+ T cell infiltration was significantly reduced in the CSLA group, while ART and SDG single drugs showed no significant changes; Foxp3 staining: The proportion of Foxp3+ Treg cells was highest in the CSLA group; Ki67 and cleaved caspase3 staining: Proliferation was enhanced and apoptosis was reduced in the CSLA group.
[0107] 5. Alcian blue staining. Alcian blue staining was used to assess changes in the colonic mucus layer. The results showed that the mucus layer almost disappeared in the model group, partially recovered in the ART and SDG groups, and significantly improved in the thickness and coverage of the mucus layer in the SLA and CSLA groups, with the CSLA group showing the best results.
[0108] Example 6
[0109] In vivo distribution and retention experiments.
[0110] Healthy C57BL / 6J mice were fasted for 12 hours and then administered FITC-labeled SLA nanoparticles and CSLA nanoparticles by gavage, respectively. Fluorescence images were acquired using a small animal in vivo imaging system (IVIS) at 2, 12, and 24 hours post-administration. Results showed that at 2 hours, both groups exhibited significant fluorescence in the gastrointestinal tract; at 12 hours, the fluorescence in the SLA group significantly decreased, while the CSLA group maintained a strong signal; at 24 hours, the signal in the SLA group almost disappeared, while a significant intestinal retention signal was still detectable in the CSLA group. Imaging of the isolated gastrointestinal tract after mouse sacrifice yielded results consistent with in vivo imaging.
[0111] Example 7
[0112] Safety assessment.
[0113] 1. Acute toxicity (safety in the DSS model). Serum from mice in each treatment group in Example 5 was collected to detect liver function indicators ALT, AST, and kidney function indicator Cre. The results showed that ALT, AST, and Cre were significantly elevated in the DSS model group; ART, SDG, SLA, and CSLA all recovered after treatment, with the CSLA group showing the most significant recovery. H&E staining of heart, liver, kidney, stomach, and tongue tissues revealed no obvious drug-related pathological changes.
[0114] 2. Long-term toxicity. Healthy C57BL / 6J mice were administered CSLA nanoparticles (at the same dose as before) by gavage for 2, 4, and 6 weeks, with 6 mice in each group. Serum samples were collected at each time point to detect ALT, AST, and Cre, and tissues from the heart, liver, lung, kidney, stomach, and tongue were collected for H&E staining. The results showed that there were no significant differences in serum indicators compared with the normal control group at each time point; no histological abnormalities were found in any organ.
[0115] Example 8
[0116] 1. Sample preparation and sequencing. Colon tissues from mice in the DSS model group and CSLA treatment group in Example 5 were collected, and single-cell suspensions were prepared for single-cell transcriptome sequencing using the 10x Genomics platform.
[0117] 2. Data Analysis. Raw data were processed using Cell Ranger and aligned to the mouse reference genome mm10. Seurat software was used for quality control, dimensionality reduction clustering, and cell type annotation. Results showed that major cell groups were identified, including macrophages, neutrophils, goblet cells, T cells, B cells, and fibroblasts.
[0118] 3. Differential expression analysis. Gene expression changes were compared between the two groups in different cell types: In macrophages, the CSLA group downregulated Clec4e, Cd14, S100a8, and Nos2, and upregulated Arg1 and Il10; in neutrophils, the CSLA group downregulated Itgam, Padi4, and Mpo; in goblet cells, the CSLA group upregulated Muc2 and Tff3; the proportion of Treg cells increased, while the expression of Gzmb, Ifng, and Mmp9 was downregulated in CD8+ T cells and NK cells.
[0119] KEGG enrichment analysis showed that differentially expressed genes were significantly enriched in pathways such as NFκB, TNF, JAKSTAT, and Th17 differentiation.
[0120] The CSLA nanoparticles prepared by this invention have the following technical effects:
[0121] 1. pH-responsive release: The release rate in simulated gastric juice is almost zero after 24 hours, while the release rate in simulated intestinal juice reaches 81.94% after 24 hours; 2. Highly efficient cellular uptake: The cellular uptake rate reaches 92.5% after 24 hours; 3. Long-lasting intestinal retention: Significant intestinal retention signals can still be detected 24 hours after oral administration; 4. Significant therapeutic effect: The DAI score is reduced most significantly, the colonic tissue pathological damage is the mildest, and the MUC2 expression is restored best; 5. Good safety: No significant organ toxicity or functional abnormalities were observed with short-term and long-term administration.
[0122] The above description, in conjunction with specific preferred embodiments, provides a further detailed explanation of the present invention. It should not be construed that the specific implementation of the present invention is limited to these descriptions. For those skilled in the art, various simple deductions and substitutions can be made without departing from the inventive concept, and all such modifications and substitutions should be considered within the scope of protection of the present invention.
Claims
1. Nanoparticles for the preparation of an oral therapeutic drug for inflammatory bowel disease, characterized in that, The following preparation method was used to prepare it: First, the immunomodulator and HDAC11 inhibitor extracted from natural plants were dissolved in ethanol to prepare solutions with a concentration of 8-12 mg / mL. The two solutions were then mixed thoroughly at a mass ratio of 0.75-1:1 to obtain a first mixture. The first mixture was then added dropwise to deionized water to obtain a second mixture with an ethanol content of 8%, and the mixture was stirred for 20-28 hours. Subsequently, the ethanol was removed by dialysis to obtain an aqueous dispersion of SLA nanoparticles. Bacillus spores were taken, homogenized and crushed, and then ultracentrifuged in a 30-60% sucrose density gradient medium to separate and purify the spore outer wall fragments, thus obtaining an aqueous dispersion of coated nanoparticles. The SLA nanoparticle aqueous dispersion and the coating nanoparticle aqueous dispersion are mixed at a mass ratio of 0.75~1:1 and incubated at 35~39℃ for 2~4 hours, so that the coating nanoparticles spontaneously coat the surface of the SLA nanoparticles through electrostatic adsorption, forming CSLA nanoparticles with a core-shell structure, i.e., the target nanoparticles. The immunomodulator is artesunate; the HDAC11 inhibitor is open-ring isolarcisinol; the Bacillus spores are Bacillus coagulans spores; The dialysis was performed using a dialysis bag with a molecular weight cutoff of 10 kDa.
2. The nanoparticles according to claim 1, characterized in that, The homogenization and crushing are carried out under a pressure of 80~120MPa, and the ultracentrifugation is carried out at 150000×g for 2~6 hours.
3. The nanoparticles according to claim 1, characterized in that, The SLA nanoparticles have a particle size of 120~140nm, the polydispersity index of the SLA nanoparticle aqueous dispersion is less than 0.1, and the Zeta potential of the SLA nanoparticle aqueous dispersion is -15mV to -20mV.
4. The application of a nanoparticle in the preparation of a drug for treating inflammatory bowel disease, characterized in that, The nanoparticles are those described in any one of claims 1 to 3, and the drug for treating inflammatory bowel disease is an oral formulation.
Citation Information
Patent Citations
Colonic delivery using Zn / pectin beads with a Eudragit coating
CN101795675A
KR20220143266A
